GlassScriptPhysician profile
Jenna Kueker
NPI 1811471402
$1,416.90
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $849.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $229.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.42 | 2021-2022 | |
| Lilly USA, LLC | $138.77 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.92 | 2021-2022 | |
| Abbvie INC. | $114.98 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $106.78 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $87.24 | 2022 | |
| Kaleo, INC. | $68.61 | 2022 | |
| Novo Nordisk INC | $47.51 | 2021 | |
| Grifols USA, LLC | $46.09 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $42.58 | 2021-2022 | |
| Amarin Pharma, INC. | $38.70 | 2021 | |
| Amgen INC. | $37.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.92 | 2021-2022 | |
| Csl Behring | $27.25 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.85 | 2022 | |
| Optinose US, INC. | $18.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.35 | 2021 | |
| Genentech USA, INC. | $16.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Kueker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.